Stent Management of Leaks After Bariatric Surgery: a Systematic Review and Meta-analysis.

BACKGROUND: Despite the low rates of complications of bariatric surgery, gastrointestinal leaks are major adverse events that increase post-operative morbidity and mortality. Endoscopic treatment using self-expanding stents has been used in the therapeutic management of these complications with preliminary good results. METHODS: We performed a systematic review and meta-analysis of self-expanding stents placement for the management of gastrointestinal leaks after obesity surgery. Overall proportion of successful leak closure, stent migration, and reoperation were analysed as primary outcomes. Secondary outcomes were patients' clinical characteristics, duration and type of stent, other stent complications, and mortality. RESULTS: A meta-analysis of studies reporting stents was performed, including 488 patients. The overall proportion of successful leak closure was 85.89% (95% CI, 82.52-89.25%), median interval between stent placement and its removal of 44 days. Stent migration was noted in 18.65% (95% CI, 14.32-22.98%) and the overall proportion of re-operation was in 13.54% (95% CI, 9.94-17.14%). The agreement between reviewers for the collected data gave a Cohen's κ value of 1.0. No deaths were caused directly by complications with the stent placement. CONCLUSIONS: Endoscopic placement of self-expanding stents can be used, in selected patients, for the management of leaks after bariatric surgery with a high rate of effectiveness and low mortality rates. Nevertheless, reducing stent migration and re-operation rates represents an important challenge for future studies.

Análisis del impacto de la cirugía bariátrica en el gasto farmacológico a medio plazo / Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure

Introducción: La obesidad y las enfermedades asociadas a ella suponen un importante problema, y no solo sanitario, sino también económico, ya que muchas de esas patologías son subsidiarias de tratamiento farmacológico de por vida. La cirugía bariátrica y metabólica, a priori, disminuye la demanda de medicamentos de estos pacientes, pero puede condicionar otro tipo de necesidades farmacológicas. El objetivo del estudio es demostrar si existe un descenso real del gasto farmacológico tras la cirugía bariátrica. Material y métodos: Análisis retrospectivo transversal de los pacientes intervenidos en nuestro centro entre 2012 y 2016, comparando las distintas comorbilidades y los gastos farmacológicos asociados a ellas un mes antes y a los 2años de la cirugía. Resultados: Fueron intervenidos 400 pacientes. Se presentaron los resultados mostrando para cada una de las técnicas quirúrgicas estudiadas las diferencias entre la resolución de las distintas comorbilidades y el ahorro farmacológico generado. La comorbilidad más coste-efectiva del estudio fue la diabetes mellitus tipo2 (DM2). La técnica quirúrgica con mejores resultados fue el bypass metabólico, presentando una diferencia de costes tras la cirugía de 507euros mensuales (p<0,001). Conclusiones: En un seguimiento de 2años tras la cirugía bariátrica se produce un descenso en la prevalencia de las enfermedades asociadas a la obesidad y del gasto farmacológico asociado a ellas, lo que demuestra que este tipo de intervención resulta eficiente a medio plazo. (AU)

Introduction: Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery. Material and methods: Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2years after surgery. Results: 400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507euros per month (P<.001). Conclusions: In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term. (AU)

Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure.

INTRODUCTION: Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery. MATERIAL AND METHODS: Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2 years after surgery. RESULTS: 400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type 2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507 euros per month (P < 0.001). CONCLUSIONS: In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term.

Mastopatía diabética. Revisión sistemática con 93 pacientes / Diabetic mastopathy. A systematic review of 93 patients

Introducción La mastopatía diabética (MD) es una afectación benigna de la mama que aparece en pacientes diabéticas con mal control glucémico de larga evolución. La enfermedad se caracteriza por la aparición de nódulos fibrosos que pueden simular tanto clínica como radiológicamente un cáncer de mama. Su diagnóstico debe realizarse con biopsia con aguja gruesa (BAG) y el tratamiento debe evitar resecciones quirúrgicas. El objetivo de este trabajo es caracterizar con más exactitud esta enfermedad y sus características aportando claridad en su diagnóstico diferencial. Material y métodos Se ha realizado una revisión sistemática de los artículos publicados en los últimos 5 años en las principales bases de datos médicas usando para ello los términos «Mastopatía diabética» y «Diabetic mastopathy». Se incluyeron todo tipo de artículos científicos que aportasen datos sobre la MD, excluyendo aquellos que incluyeran otras enfermedades inflamatorias de la mama. Se seleccionaron finalmente 28 artículos. Para el análisis estadístico se dividió a las pacientes en 2 grupos, diabetes mellitus (DM) tipo 1 (DM1) y DM tipo 2 (DM2), y se compararon la media y la proporción de las diferentes variables analizadas utilizando para ello la prueba t de Student. Se utilizó el programa STATA para realizar el análisis estadístico. Resultados Se analizaron 28 artículos, con un total de 93 pacientes incluidas. En los artículos analizados todos los pacientes eran mujeres. La mayoría de las pacientes presentaron DM1 y el tiempo medio de evolución de la diabetes fue de 20 años. La lesión asociada a la DM que se observó con mayor frecuencia fue la retinopatía diabética (34%). La lesión palpable fue la forma de manifestación más frecuente (53%). Respecto al diagnóstico el hallazgo mamográfico más habitual, fue la hiperdensidad asimétrica y en la ecografía la lesión hipoecoica de bordes irregulares y sombra acústica posterior. El tratamiento más habitual fue conservador. Conclusión ... (AU)

Introduction Diabetic mastopathy is a benign disease of the breast that develops in patients with long-standing diabetes and poor glycemic control. The disease is characterised by fibrous nodules that can be confused with breast cancer both clinically and radiologically. Diagnosis should be made with core needle biopsy (CNB) and treatment should avoid surgical resections. The main objective of this study was to characterise this rare disease in order to improve its differential diagnosis and treatment. Material and methods A systematic review was conducted, including articles published in the last 5 years in the main medical databases using the terms “Mastopatía diabética” and “Diabetic mastopathy”. We included all types of scientific articles providing data on diabetic mastopathy. We excluded articles including other inflammatory breast diseases. Finally 28 articles were selected. For the statistical analysis, patients were divided in 2groups: DM1 patients and DM2 patients. The mean and proportion of the different variables were analysed with the Student t-test. The statistical analysis was performed with the STATA programme. Results We analysed 28 articles, with 93 patients. None of the included articles reported male patients. Most patients had type 1 diabetes and diabetic mastopathy developed at a mean of 20 years after diabetes onset. The most frequent complication of diabetes was diabetic retinopathy (34%). The most common manifestation was a palpable nodule (53%). Regarding diagnosis, the most common mammographic finding was asymmetric hyperdensity and the most common ultrasound finding was a hypoechoic lesion with irregular edges and posterior acoustic shadow. The most frequent treatment was conservative. Conclusion... (AU)

Quiste tímico: una entidad rara en el adulto / Thymic Cysts: A Rare Entity in Adults

No disponible

Bull horn injuries. A 40-year retrospective study with 572 patients.

BACKGROUND: Although bullfighting festivals were traditionally attributed to the cultural idiosyncrasies of the Ibero-American people, they also exist world-wide. METHODS: A retrospective study was conducted, reviewing the medical records of patients treated on our service for bull horn injuries between January 1978 and December 2019. RESULTS: There were 572 admissions due to bull horn injuries. 54 of these patients had multiple injuries. The average annual admission was 13.6 patients. The most frequent injuries were located in the lower extremities, perineum, and abdomen. Forty-seven laparotomies were performed, revealing intra-abdominal visceral impairment on 39 occasions. The most frequently injured organs were the intestine and liver. The most frequent complications were skin devitalisation, infection and post-operative eventration. The recorded mortality was 0.87%. CONCLUSION: We wish to highlight the importance of injuries caused by bull horns worldwide. These are high-impact injuries with specific intrinsic characteristics that require regulated medical and surgical care.

Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure. / Análisis del impacto de la cirugía bariátrica en el gasto farmacológico a medio plazo.

INTRODUCTION: Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery. MATERIAL AND METHODS: Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2years after surgery. RESULTS: 400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507euros per month (P<.001). CONCLUSIONS: In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term.

Tumor de células granulares. Abrikossoff de la mama, presentación de un caso tratado en nuestro centro / Granular cell tumour. Abrikossof tumour of the breast. Report of a case treated in our centre

El presente artículo describe nuestra experiencia en el diagnóstico y tratamiento de un paciente varón de 42 años diagnosticado de un tumor de células granulares en la mama y pretende llamar la atención sobre esta entidad, que puede simular un carcinoma de mama, debiéndose tener en cuenta en el diagnóstico diferencial de la enfermedad nodular mamaria

This article describes our experience in the diagnosis and treatment of a 42-year-old male patient diagnosed with a granular cell tumour in the breast and draws attention to this entity, which can simulate a breast carcinoma. This should be taken into account in the differential diagnosis of nodular breast disease

Síndrome de la mama fantasma posmastectomía. Estudio de prevalencia y características clínicas en un hospital de tercer nivel / Post-mastectomy phantom breast syndrome. Study of prevalence and clinical characteristics in a tertiary hospital

Objetivo: Conocer la prevalencia y características del síndrome de la mama fantasma en nuestro entorno. Pacientes y métodos: Se realizó una encuesta telefónica a 50 mujeres mastectomizadas entre los años 2002 y 2009 en el Hospital General Universitario de Castellón. Se preguntó sobre la presencia de dolor antes del diagnóstico de la enfermedad y de la cirugía, del síndrome de dolor posmastectomía y del síndrome de la mama fantasma, ampliando el interrogatorio en caso de respuesta afirmativa para conocer las características de la sintomatología, el momento de aparición, la frecuencia de aparición, la duración de la clínica y la necesidad o no de tratamiento farmacológico específico en cada síndrome. Se realizó un análisis descriptivo de los datos obtenidos. Resultados: El 76% de las mujeres interrogadas presentaron algún tipo de sensación extraña o dolorosa en la zona de la cicatriz mamaria, de las cuales el 65,8% presentó sensaciones no dolorosas y el 34,2% dolorosas. El síndrome de la mama fantasma apareció en el 38% de las mujeres interrogadas, y en muchos de los casos (31,6%) de las que respondieron afirmativamente se expresaba en forma de picor en el pezón ausente. Conclusiones: El síndrome de dolor posmastectomía y el síndrome de la mama fantasma son entidades poco conocidas, aunque prevalentes en nuestro medio. Tienen un carácter complejo y multifactorial, por lo que es importante conocerlas para conseguir un correcto tratamiento de las pacientes afectas, y así mejorar su calidad de vida

Objective: To determine the prevalence of post-mastectomy pain syndrome and phantom breast syndrome in our environment. Patients and methods: We performed a telephone survey of 50 women who underwent mastectomy between 2002 and 2009 in the General Hospital of Castellon (Spain). The women were asked about the presence of pain before diagnosis of the disease and surgery, post-mastectomy pain syndrome, and phantom breast syndrome. Women with symptoms were asked about their characteristics, time of onset, frequency, duration, and whether or not a specific pharmacological treatment was needed for each syndrome. A descriptive analysis was performed of the data obtained. Results: A total of 76% of the women surveyed had some kind of strange or painful sensation in the breast scar, 65.8% of whom had painless sensations and 34.2% had painful sensations. Phantom breast syndrome appeared in 38% of the surveyed women and manifested as an itch in the absent nipple in 31.6% of the women. Conclusions: Post-mastectomy pain syndrome and phantom breast syndrome are little known entities, although they prevalent in our environment. These syndromes are complex and multifactorial; therefore, familiarity with their characteristics is essential to provide affected women with proper treatment and improve their quality of life

Idiopathic granulomatous mastitis: A systematic review of 3060 patients.

Idiopathic granulomatous mastitis is a rare benign breast disease. A systematic review was designed. Clinical and therapeutic characteristics were analyzed. Human Development Index (HDI) was used to define two groups of study: group A (very high and high HDI) and group B (medium and low HDI). Corticosteroid therapy was done in 69% group A and 78% group B. Surgery was done in 63% in group A and 83% in group B. Antibiotics were used in 68% group A and 88% group B. There is no consensus about optimal treatment for granulomatous mastitis.

¿Se ha incrementado la incidencia del cáncer de mama en la mujer joven? Análisis de un registro poblacional de tumors / Has the incidence of breast cancer increased in young women? Analysis of a population-based tumour registry

Introducción. El cáncer de mama en la mujer joven constituye cerca del 5-10% de los cánceres de mama. Recientes estudios han demostrado un aumento de la incidencia de cáncer de mama en la mujer joven pero es posible que estos resultados no sean aplicables a nuestro entorno. El objetivo del presente estudio fue analizar si en nuestro entorno ha habido un aumento real de la incidencia. Material y métodos. Se utilizaron los datos del registro poblacional de tumores de mama de la provincia de Castellón (Comunidad Valenciana, España), correspondientes al Hospital Universitario General de Castellón en el periodo 1995-2013. Se establecieron 3grupos: < 45 años, de 45 a 69 años y > 69 años. Se realizó otra división en menores y mayores de 40 años. Resultados. De los 1.416 casos analizados, 178 eran menores de 45 años (12,6%), 886 (62,6%) tenían entre 45 y 69 años, y 352 (24,9%) tenían > 69 años. Del total, 87 pacientes fueron menores de 40 años (6,1%). El número de casos diagnosticados entre los 45 y los 69 años se ha visto incrementado de manera progresiva. Por el contrario, el número de casos diagnosticados en pacientes menores de 45 años se mantuvo prácticamente constante durante todos los años de estudio. La incidencia en mujeres menores de 40 años se mantuvo casi constante durante los años de estudio. Conclusión. No se ha podido demostrar en nuestro entorno y en el periodo estudiado un aumento de incidencia en el número de casos de mujeres jóvenes, tanto cuando se establecieron los puntos de corte en 40 años o en 45 años

Introduction. Breast cancer in young women represents only 5-10% of breast cancers. Recent studies have demonstrated an increasing incidence of breast cancer in young women, but these results may not apply in our population. The objective of this study was to analyse whether there has been a real increase in the incidence of breast cancer in young women in our population. Material and methods. Data were retrieved from the Castellon Cancer Registry (C. Valenciana, Spain), a population-based cancer registry. Data from tumours diagnosed in Castellon General Hospital between 1995 and 2013 were used to conduct this study. We defined 3groups of patients: <45 years; 45-69 years and >69 years. Another analysis was performed, using a cutoff at 40 years. Results. Of the 1,416 patients analysed, 178 were aged <45 years (12.6%), 886 (62.6%) were aged between 45 and 69 years and 352 (24.9%) were > 69 years; 87 patients were <40 years old (6.1%). The number of incident breast cancer patients significantly increased in the group aged 45-69 years. However, the number of incident cases remained constant during the study period for both patients aged <45 years and those aged <40 years. Conclusion. We did not find an increase in the incidence of breast cancer in young women in our population in the period analysed, or in women aged <45 years or <40 years old

Breast cancer in octogenarian. Are we doing our best? A population-registry based study.

BACKGROUND: The number of old people with breast cancer is estimated to increase during the next years in developed countries. However, management of breast cancer in octogenarians is not well established. The main objective was to evaluate if patients older than 80 years with breast cancer are receiving the most convenient treatment by using a population registry cancer analysis. PATIENTS AND METHODS: A retrospective analysis of a population cancer registry was designed. Data were retrieved from the Castellon Cancer Registry (Valencian Community, Spain). Patient records were analyzed from January 1, 1995 to December 31, 2013. Two groups were defined: group A, <80 years; and group B, >= 80 years. Survival analyses were sequentially performed into three phases. First, a non-adjusted Kaplan Meier analysis was conducted. For the second survival analyses, Cox's proportional hazards model of Overall survival was used adjusting for condensed-TNM stage and adjuvant treatments. Finally, the third specific adjustment was carried out adding information of life expectancy by age for Spanish women, corresponding to year 2008 with condensed-TNM stage and Propensity Score variable, as an approximation to relative or disease-specific survival. RESULTS: The total number of included patients was 1304. Women ≥80 years presented a more extended disease, larger tumors and less in situ carcinomas. A lower proportion of women ≥80 years received adjuvant therapies. In the absence of any adjustment of results, the overall survival in women ≥80 years was poorer than in younger patients (median of 14.1 years for <80y vs. 5.7 years for ≥80y), the crude HR was 4.6 (95% CI: 2.9-7.5) p < 0.001. For second survival analysis, the HR was 2.5 (95% CI: 1.8-3.5) p < 0.001. After the third adjustment the HR was 1.7 (95% CI: 1.2-2.4) p = 0.004. CONCLUSIONS: Octogenarians with operable breast cancer are receiving suboptimal treatments, which can have repercussions on survival. New studies are required to identify a subgroup of women age ≥80 years who may benefit from more aggressive treatment and a population of older women on the basis of tumor characteristics, comorbidities and life expectancy who may not need as aggressive treatment.

Carcinoma medular quístico de mama / Cystic medullary breast carcinoma

No disponible

Current status of ovarian cancer in the Spanish Province of Castellon. Prognostic factors in observed and relative survival. A population cancer-registry-based study between 2004 and 2008 / Estado actual del cáncer de ovario en la provincia de Castellón. Factores pronósticos en la supervivencia observada y relativa. Un estudio basado en registros poblacionales de cáncer de entre 2004 y 2008

Background. The aim of this population-based study was to assess independent prognostic factors in ovarian cancer by analyzing observed and relative survival in a representative Spanish population. Methods. We carried out a retrospective, observational, population-registry-based study. Data on 207 patients with ovarian cancer were provided by the Castellon Cancer Registry. Observed and relative survival were described at 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with univariate and multivariate analyses. Results. The median follow-up was 40.8 months (range: 12-108 months). Observed and relative survival rates at 1, 3 and 5 years were 79%, 51%, 33%, and 84%, 58%, 40%, respectively. Age older than 70 years showed worse observed survival in the univariate and multivariate analyses. Only FIGO stage was an independent prognostic factor for observed and relative survival. Conclusions. Survival is poor in patients with ovarian cancer. In our population-registry-based study, only age at diagnosis and FIGO stage were independent prognostic factors for observed survival, whereas only FIGO stage could be considered a prognostic factor for relative survival (AU)

Antecedentes. El objetivo de este estudio poblacional fue evaluar los factores pronósticos independientes de cáncer de ovario mediante el análisis de la supervivencia observada y relativa en una población española representativa. Métodos. Se realizó un estudio retrospectivo, observacional, y basado en un registro de población. Los datos de 207 pacientes con cáncer de ovario proceden del Registro de Cáncer de Castellón. Se describió la supervivencia observada y relativa a 1, 3 y 5 años. El efecto de los factores pronósticos en la supervivencia se evaluó mediante análisis univariantes y multivariantes. Resultados. La mediana de seguimiento fue de 40,8 meses (intervalo: 12-108 meses). Las tasas de supervivencia observada y relativa a 1, 3 y 5 años fueron de 79%, 51% y 33% y de 84%, 58% y 40%, respectivamente. La edad superior a los 70 años mostró la peor supervivencia observada en los análisis univariantes y multivariantes. Sólo el estadio en la clasificación FIGO fue un factor pronóstico independiente de la supervivencia observada y relativa. Conclusiones. La supervivencia en los pacientes con cáncer de ovario es limitada. En nuestro estudio basado en un registro de población, sólo la edad en el momento del diagnóstico y el estadio de FIGO fueron factores pronósticos independientes para la supervivencia observada, mientras que sólo el estadio de la FIGO se podría considerar un factor pronóstico en la supervivencia relativa (AU)

[Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study]. / Relación del tamaño tumoral con la recidiva tras cirugía conservadora en el cáncer de mama en estadio tumoral T1-T2. Estudio poblacional.

BACKGROUND: Conservative surgery can be regarded as the standard treatment for most early stage breast tumors. However, a minority of patients treated with conservative surgery will present local or locoregional recurrence. Therefore, it is of interest to evaluate the possible factors associated with this recurrence. METHODS: A population-based retrospective study using data from the Tumor Registry of Castellón (Valencia, Spain) of patients operated on for primary nonmetastatic breast cancer between January 2000 and December 2008 was designed. Kaplan-Meier curves and log-rank test to estimate 5-year local recurrence were used. Two groups of patients were defined, one with conservative surgery and another with nonconservative surgery. Cox multivariate analysis was conducted. RESULTS: The total number of patients was 410. Average local recurrence was 6.8%. In univariate analysis, only tumor size and lymph node involvement showed significant differences. On multivariate analysis, independent prognostic factors were conservative surgery (hazard ratio [HR] 4.62; 95% confidence interval [CI]: 1.12-16.82), number of positive lymph nodes (HR 1.07; 95% CI: 1.01-1.17) and tumor size (in mm) (HR 1.02; 95% CI: 1.01-1.06). CONCLUSIONS: Local recurrence after breast-conserving surgery is higher in tumors >2 cm. Although tumor size should not be a contraindication for conservative surgery, it should be a risk factor to be considered.

Antecedentes: la cirugía conservadora es un patrón de referencia del tratamiento de la mayor parte de los tumores mamarios en estadios iniciales. Sin embargo, una minoría de pacientes intervenidas con esta opción tendrá recurrencia local o locorregional. Por ello resulta de interés evaluar los posibles factores relacionados con esta recurrencia. Material y métodos: estudio retrospectivo, con base poblacional, efectuado con base en los datos del Registro de Tumores de Castellón (Comunidad Valenciana, España) de pacientes intervenidas de cáncer primario de mama no metastático de enero de 2000 a diciembre de 2008. Se utilizaron las curvas de Kaplan-Meier y la prueba de log-rank para estimar la recurrencia local a cinco años. Se definieron dos grupos de pacientes, uno con cirugía conservadora y otro con cirugía no conservadora de la mama. Se realizó un estudio multivariado de Cox. Resultados: se encontraron 410 pacientes con promedio de 6.8% de recurrencias locales. En el análisis univariado sólo el tamaño tumoral y la afectación ganglionar demostraron diferencias significativas. En el análisis multivariado los factores pronóstico independientes fueron: la cirugía conservadora (Hazard ratio [HR] 4.62; IC [intervalo de confianza] 95% 1.12-16.82), el número de ganglios linfáticos positivos (HR 1.07; IC 95% 1.01-1.17) y el tamaño del tumor en milímetros (HR 1.02; IC 95% 1.01-1.06). Conclusiones: la recurrencia local postcirugía conservadora de mama es mayor en tumores de más de 2 cm. Aunque el tamaño del tumor no debería ser una contraindicación para esta cirugía sí deben tomarse en cuenta como un factor de riesgo.

Rentabilidad diagnóstica de la punción percutánea pancreática en función del tamaño de la lesión / Diagnostic yield of pancreatic percutaneous puncture depending on the size of the lesion

Introducción El objetivo del presente estudio fue analizar la eficacia diagnóstica de la punción percutánea de tejido pancreático. Material y métodos Estudio retrospectivo de pacientes con sospecha de neoplasia de origen pancreático, con biopsia percutánea de tejido pancreático, desde el 2000 hasta el 2011. Para el análisis estadístico comparativo se estratificó la muestra por tamaño, en menores o iguales a 3 cm frente a mayores. Resultados Se realizaron un total de 90 biopsias. Se llegó al diagnóstico de neoplasia pancreática en 47 casos (52%), 16 falsos negativos (18%), 0 falsos positivos y al de pancreatitis crónica en 24 casos (27%). Los resultados de rendimiento de la prueba fueron: sensibilidad (S) global del 75% (intervalo de confianza [IC] 95%: 62-85%), especificidad (E) del 100% (IC 95%: 87-100%), valor predictivo positivo (VPP) del 100% (IC 95%: 92-100%) y valor predictivo negativo (VPN) del 63% (IC 95%: 46-77%). En masas ≤ 3 cm la S fue del 70% (IC 95%: 45-88%), la E del 100% (IC 95%: 66-100%), el VPP del 100% (IC 95%: 76-100%) y el VPN 60% (IC 95%: 32-83%). Frente a masas mayores de 3 cm que presentaron una S del 88% (IC 95%: 70-98%), una E del 100% (IC 95%: 75-100%), un VPP del 100% (IC 95%: 85-100%) y un VPN del 81% (IC 95%: 54-96%).Conclusiones La rentabilidad de la biopsia percutánea pancreática está fuertemente condicionada por el tamaño de la lesión. Para tamaños tumorales menores de 3 cm la sensibilidad y el valor predictivo negativo son inaceptablemente bajos, porque lo que resultados negativos no serían fiables (AU)

Introduction The aim of the present study was to study the diagnostic efficacy of the percutaneous puncture of pancreatic tissue. Material and methods A retrospective study was conducted on patients with suspicion of pancreatic neoplasm, and with a percutaneous biopsy of pancreatic tissue, from 2000 to 2011. For the statistical comparative analysis, the sample was stratified by tumour size: ≤ 3 cm and > 3 cm. Results A total of 90 biopsies were performed. Pancreatic neoplasm diagnosis was made in 47 cases (52%), with 16 false negatives (18%), no false positives, and chronic pancreatitis in 24 cases (27%). The efficacy of the test results were: an overall sensitivity of 75% (95% CI: 62%-85%), a specificity of 100% (95% CI: 87%-100%), a positive predictive value of 100% (95% CI: 92%-100%), and a negative predictive value of 63% (95% CI: 46%-77%). For tumour sizes ≤ 3 cm the sensitivity was 70% (95% CI: 45%-88%), with a specificity of 100% (95% CI 66%-100%), a positive predictive value of 100% (95% CI: 76%-100%, and a negative predictive value 60% (95% CI: 32%-83%). For tumours greater than 3 cm, the sensitivity was 88% (95% CI: 70%-98%), the specificity was 100% (95% CI: 75%-100%), with a positive predictive value of 100% (95% CI: 85%-100%) and a negative predictive value of 81% (95% CI: 54%-96%).Conclusions Pancreatic percutaneous biopsy efficacy was strongly determined by lesion size. For tumour sizes less than 3 cm, the sensitivity and negative predictive value are unacceptably low, as negative results would not reliable (AU)

[Diagnostic yield of pancreatic percutaneous puncture depending on the size of the lesion]. / Rentabilidad diagnóstica de la punción percutánea pancreática en función del tamaño de la lesión.

INTRODUCTION: The aim of the present study was to study the diagnostic efficacy of the percutaneous puncture of pancreatic tissue. MATERIAL AND METHODS: A retrospective study was conducted on patients with suspicion of pancreatic neoplasm, and with a percutaneous biopsy of pancreatic tissue, from 2000 to 2011. For the statistical comparative analysis, the sample was stratified by tumour size: ≤ 3cm and > 3cm. RESULTS: A total of 90 biopsies were performed. Pancreatic neoplasm diagnosis was made in 47 cases (52%), with 16 false negatives (18%), no false positives, and chronic pancreatitis in 24 cases (27%). The efficacy of the test results were: an overall sensitivity of 75% (95% CI: 62%-85%), a specificity of 100% (95% CI: 87%-100%), a positive predictive value of 100% (95% CI: 92%-100%), and a negative predictive value of 63% (95% CI: 46%-77%). For tumour sizes ≤ 3cm the sensitivity was 70% (95% CI: 45%-88%), with a specificity of 100% (95% CI 66%-100%), a positive predictive value of 100% (95% CI: 76%-100%, and a negative predictive value 60% (95% CI: 32%-83%). For tumours greater than 3cm, the sensitivity was 88% (95% CI: 70%-98%), the specificity was 100% (95% CI: 75%-100%), with a positive predictive value of 100% (95% CI: 85%-100%) and a negative predictive value of 81% (95% CI: 54%-96%). CONCLUSIONS: Pancreatic percutaneous biopsy efficacy was strongly determined by lesion size. For tumour sizes less than 3cm, the sensitivity and negative predictive value are unacceptably low, as negative results would not reliable.